Teachers Advisors’s Axsome Therapeutics AXSM Stock Holding History

Teachers Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-17,034	Closed	-$66K	–	3130
2017 Q1	$66K	Hold	17,034	–	–	﹤0.01%	3022
2016 Q4	$115K	Hold	17,034	–	–	﹤0.01%	2994
2016 Q3	$134K	Hold	17,034	–	–	﹤0.01%	2974
2016 Q2	$128K	Buy	+17,034	New	+$157K	﹤0.01%	3015

Other funds holding AXSM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Teachers Advisors's AXSM Position: Q2 2017 in Review

Teachers Advisors sold out of Axsome Therapeutics (AXSM) in Q2 2017, closing a stake of 17,034 shares — an estimated $66K sold.

Teachers Advisors first reported a position in AXSM in Q2 2016 and held it in 4 quarters. The position peaked at $134K in Q3 2016. 35 funds tracked by Wall St. Rank hold AXSM as of Q2 2017.

Teachers Advisors reported no remaining Axsome Therapeutics position as of Q2 2017 after selling out during the quarter.
Teachers Advisors sold 17,034 Axsome Therapeutics shares in Q2 2017, an estimated $66K.
Teachers Advisors first reported a position in Axsome Therapeutics in Q2 2016 and held it in 4 quarters.
Teachers Advisors's Axsome Therapeutics position peaked at $134K in Q3 2016.
35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2017.

Based on Teachers Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.